Loading
Inflammasome and Immune Disorders · Journal article
Science Signaling · August 18, 2026
Raises a question worth testing. It does not answer one.
This is a discovery study using unbiased genome-wide CRISPR screening in monocyte cell lines to map genes regulating type I interferon induction via the cGAS-STING pathway. The work identifies candidate regulators, including previously uncharacterized genes and a cooperative role for TBL1XR1 and HDAC3 in supporting IFNB1 expression, and serves as a mechanistic and genetic resource but does not establish clinical utility or validate findings in primary human cells or in vivo.
Functional genomics discovery study; genome-wide CRISPR screen. THP-1 monocyte-like cells, cultured in unprimed state and primed with interferon-alpha. Intervention: Genome-wide CRISPR knockout screen targeting genes regulating cGAS-STING–induced type I interferon response.
Distinct subsets of genes regulated IFNB1 induction in unprimed versus IFN-α-primed THP-1 cells NCoR/SMRT corepressor complex components TBL1XR1 and HDAC3 cooperate to support IFNB1 expression HDAC3 promotes activation of TBK1, an essential kinase driver of type I interferon responses
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This resource identifies candidate genes for future investigation in inborn errors of immunity and cancer; findings may inform development of STING pathway modulators for interferonopathies. However, results are limited to cell lines and require validation in primary human cells and animal models before clinical translation.
Genome-wide CRISPR screening in cell lines identifies candidate genes regulating interferon induction, providing mechanistic insights and a resource for future studies but not clinical evidence of efficacy or causation in disease.
As stated by the source record.
This resource identifies candidate genes for future investigation in inborn errors of immunity and cancer; findings may inform development of STING pathway modulators for interferonopathies. However, results are limited to cell lines and require validation in primary human cells and animal models before clinical translation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Type I interferons (IFNs) are induced by pattern recognition receptors (PRRs) of the innate immune system to protect against foreign pathogens and malignant transformation, and their production must be tightly regulated to balance antiviral defense with tissue homeostasis. To define the genetic network that governs IFN regulation, we conducted genome-wide CRISPR screens for genes that positively or negatively regulated IFNB1 gene expression induced by the PRR cGAS and its downstream effector STING, in both unprimed THP-1 cells and cells primed with IFN-α to mimic an ongoing inflammatory response. Distinct subsets of genes affected IFNB1 induction in the unprimed and primed states, and many regulators had not previously been associated with IFN responses, thereby linking IFNB1 regulation to various cellular pathways. For example, we found that the NCoR/SMRT corepressor complex components TBL1XR1 and HDAC3 cooperated to support IFNB1 expression, with HDAC3 promoting activation of the kinase TBK1, an essential driver of type I IFN responses. These datasets are a resource for identifying genes associated with type I IFN–related inborn errors of immunity and cancer and for developing therapies to modulate STING signaling in interferonopathies and other conditions of dysregulated type I IFN.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.